Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Metrics to compare | XLO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXLOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.4x | −6.3x | −0.5x | |
PEG Ratio | −0.03 | 0.01 | 0.00 | |
Price / Book | 1.3x | 3.4x | 2.6x | |
Price / LTM Sales | 1.1x | 7.8x | 3.2x | |
Upside (Analyst Target) | 140.7% | 41.6% | 47.4% | |
Fair Value Upside | Unlock | 12.8% | 6.9% | Unlock |